statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Biotech Innovations Aim to Combat Soaring Cancer Diagnoses by 2050 Biotech Innovations Aim to Combat Soaring Cancer Diagnoses by 2050 PR Newswire VANCOUVER, BC, May 1, 2024 USA News Group Commentary...

Biotech Innovations Aim to Combat Soaring Cancer Diagnoses by 2050

The Executive Chairman and Global Chief Scientific and Medical Officer of ImmunityBio, Inc. (NASDAQ: IBRX), a next-generation immunotherapy company, will discuss the implications of the recent FDA...

ImmunityBio Executive Chairman Dr. Patrick Soon-Shiong to Discuss ANKTIVA Approval in Fireside Chat at the Annual Conference of the American Urological Association

ImmunityBio said the QUILT 3.055 trial shows median overall survival almost double that of standard of care chemotherapy in 2nd- and 3rd-line non-small cell lung cancer (NSCLC) patients whose cancer...

What's Going On With ImmunityBio Stock?

ImmunityBio, Inc. (NASDAQ: IBRX), an immunotherapy company, today announced positive overall survival results in the QUILT 3.055 study of 2nd- and 3rd-line NSCLC patients who progressed after...

ImmunityBio Announces Positive Overall Survival Results of Anktiva Combined With Checkpoint Inhibitors in Non-Small Cell Lung Cancer; Meeting Scheduled with FDA to Discuss Registration Path for ANKTIVA in Lung Cancer

This is a signal that IBRX's price trend could be reversing, and it may be an opportunity to buy the stock or explore call options...

ImmunityBio (IBRX, $5.33) Stochastic Oscillator left the oversold zone on April 01, 2024

Over the last three days, A.I.dvisor has detected that IBRX's AroonUp green line (see chart) is above 70, while the AroonDown red line is below 30. When the green line goes above 70 while the red...

ImmunityBio (IBRX, $5.33) Aroon Indicator entered an Uptrend on April 01, 2024.

ImmunityBio (IBRX, $5.35) Aroon Indicator entered an Uptrend on March 28, 2024.

ImmunityBio (NASDAQ:IBRX  Free Report) had its price objective hoisted by Piper Sandler from $4.00 to $5.00 in a research report released on Monday, Benzinga reports. Piper Sandler currently...

Piper Sandler Raises ImmunityBio (NASDAQ:IBRX) Price Target to $5.00

ImmunityBio (IBRX, $5.45) Aroon Indicator entered an Uptrend on March 27, 2024.

ImmunityBio (IBRX, $5.13) Aroon Indicator entered an Uptrend on March 26, 2024.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

Volume	12.8M
52-Wk High	$10.53
52-Wk Low	$1.25

Period	Estimated	Reported	Surprise	Result
Q1'24	-$0.20	--	--	N/A
Q4'23	-$0.18	--	--	N/A
Q3'23	-$0.26	--	--	N/A
Q2'23	-$0.24	--	--	N/A
Q1'23	-$0.27	--	--	N/A

IBRX ImmunityBio Inc

About

Feed

News

Sentiment

Earnings

Fundamentals